Skip to main content
micro-community-banner
 
  • Saved

made a Post

KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting - PubMed

In advanced stage non-small cell lung cancer (NSCLC) patients, Kirsten Rat Sarcoma Viral Oncogene Homolog ( KRAS ) testing may soon acquire a predictive significance to select patients for AMG510 ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/32802465/

  • Saved

made a Post

Abstract 709: The utility of plasma ctDNA for detection of KRAS G12C and other mutations in lung cancers

Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA Background: KRAS is the most common oncogene in lung cancer, but has historically been considered undruggable. ..... see more

Source : https://cancerres.aacrjournals.org/content/80/16_Supplement/709

  • Saved

made a Post

Abstract 709: The utility of plasma ctDNA for detection of KRAS G12C and other mutations in lung cancers

Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA Background: KRAS is the most common oncogene in lung cancer, but has historically been considered undruggable. ..... see more

Source : https://cancerres.aacrjournals.org/content/80/16_Supplement/709

  • Saved

made a Post

Abstract 2705: Visualization of KRAS point mutations in non-small cell lung cancer tumors with morphological context using the BaseScope in situ hybridization assay

Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA About 25% of non-small cell lung cancer (NSCLC) patients bear one or more KRAS mutations in ..... see more

Source : https://cancerres.aacrjournals.org/content/80/16_Supplement/2705

  • Saved

from Pathologist Connect made a Post

Interesting findings... The clinical courses, including tumor stage at diagnosis, presence of brain metastasis, OS and RFS, are similar among lung adenocarcinoma patients with different KRAS mutation subtypes.

see more

Mayer Gorbaty, Louay Hanna Commented on a Post
  • Saved

Advancements in biomarker targeting

KRAS is the most common driver mutation in NSCLC. KRAS G12C represents nearly half (44%) of all KRAS mutations in NSCLC.

Normal KRAS protein cycles between an active and inactive form, regulating normal cell proliferation, differentiation, and survival. The KRAS G12C mutation favors the active form of the KRAS mutant protein, supporting cancer cell growth and survival.

Based on the rapid developments in biomarkers over the past few years, how quickly would you move to incorporate the testing and treatment of a new actionable biomarker?

How would you manage current patients who were previously biomarker negative, or who had progressed on treatment with another targeted agent? Would you re-test them looking for the new biomarker?

  • Saved

from Pathologist Connect made a Post

The KRAS (G12C) inhibitor AMG 510 shows very encouraging results in the first study (Canon and Rex 2019 Nature).

  • Saved

made a Post

Abstract 1086: Downstream kinase signaling is dictated by specific KRAS mutations

Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA Oncogenic KRAS mutations are common in colorectal cancer (CRC), found in ~50% of tumors, and are ..... see more

Source : https://cancerres.aacrjournals.org/content/80/16_Supplement/1086

  • Saved

made a Post

Abstract 5891: Plasma-based BDA-NGS test holds potential in circulating nucleic acid based oncogenic aberration detection

Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA Introduction: Liquid biopsy has been increasingly acknowledged as a substitute of invasive tissue biopsies in the ..... see more

Source : https://cancerres.aacrjournals.org/content/80/16_Supplement/5891

  • Saved

made a Post

Abstract 3855: Oncogenic Kras-mediated regulation of the tumor microenvironment in lung cancer

Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA Lung cancer remains the leading cause of cancer-related deaths worldwide, with an estimated 1.6 million deaths ..... see more

Source : https://cancerres.aacrjournals.org/content/80/16_Supplement/3855

54-Year-Old NSCLC Patient with KRAS G12C Mutation

Suzanne is a 54-year-old business owner with a previous smoking history. She presented with shortness of breath and a ..... see more

  • Saved

made a Post


Integrated intErventional bronchoscopy in the treatment of locally adVanced non-small lung cancER with central Malignant airway Obstructions: a multicentric REtrospective study (EVERMORE) - Lung Cancer - X-MOL

Lung Cancer--Integrated intErventional bronchoscopy in the treatment of locally adVanced non-small lung cancER with central Malignant airway Obstructions: a multicentric REtrospective study see more

Source : https://www.x-mol.com/paper/1290016381757693952

  • Saved

Commented on 's Post

Molecular epidemiology and diagnostics of KRAS mutations in human cancer

RAS mutation is the most frequent oncogenic alteration in human cancers. KRAS is the most frequently mutated followed by NRAS. The emblematic KRAS mutant cancers are pancreatic, colorectal, lung adenocarcinomas ..... see more

Source : https://link.springer.com/article/10.1007/s10555-020-09915-5

  • Saved

from Pathologist Connect made a Post

How are everyone’s multidisciplinary tumor conferences going in this new COVID world of virtual meetings?

For us, a few hiccups at the beginning, but honestly, I have to ..... see more

  • Saved

made a Post

Time-saving method for directly amplifying and capturing a minimal amount of pancreatic tumor-derived mutations from fine-needle aspirates using digital PCR

It is challenging to secure a cytopathologic diagnosis using minute amounts of tumor fluids and tissue fragments. Hence, we developed a rapid, accurate, low-cost method for detecting tumor cell-derived DNA ..... see more

Source : https://www.nature.com/articles/s41598-020-69221-6

  • Saved

made a Post

Structure-based inhibitor design of mutant RAS proteins-a paradigm shift

As a member of small GTPase family, KRAS protein is a key physiological modulator of various cellular activities including proliferation. However, mutations of KRAS present in numerous cancer types, most ..... see more

Source : https://link.springer.com/article/10.1007/s10555-020-09914-6

  • Saved

made a Post

Precision Medicine in Non-Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation

Non-small cell lung cancer (NSCLC) has become a prominent example of precision medicine among solid tumor malignancies. Clinical management of NSCLC now depends on surgical, chemotherapeutic, and radiation treatment regimens ..... see more

Source : https://ascopubs.org/doi/full/10.1200/EDBK_209089

  • Saved

made a Post

Fibroblast Growth Factor-14 Acts as Tumor Suppressor in Lung Adenocarcinomas

Investigation of the molecular dynamics in lung cancer is crucial for the development of new treatment strategies. Fibroblast growth factor (FGF) 14 belongs to the FGF family, which might play ..... see more

Source : https://www.mdpi.com/2073-4409/9/8/1755/htm

  • Saved

Commented on 's Post

Association of RAS Mutation Location and Oncologic Outcomes After Resection of Colorectal Liver Metastases

RAS mutations are prognostic for patients with metastatic colorectal cancer (mCRC). We investigated clinical, pathologic, and survival differences based on RAS exon for patients with colorectal liver metastases (CRLM). This ..... see more

Source : https://link.springer.com/article/10.1245/s10434-020-08862-3

  • Saved

from Pathologist Connect made a Post

Hello everyone. I am a pathologist, new to the group, and looking forward to engaging with everyone in lively discussion. Here is one of my favorite KRAS images. I frequently ..... see more